Copyright Reports & Markets. All rights reserved.

Global Oncolytic Virus Cancer Immunotherapy Market Status and Forecast 2021-2027

Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Status and Forecast (2016-2027)
      • 1.3.2 Global Oncolytic Virus Cancer Immunotherapy Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Oncolytic Virus Cancer Immunotherapy Supply by Company

    • 2.1 Global Oncolytic Virus Cancer Immunotherapy Sales Value by Company
    • 2.2 Oncolytic Virus Cancer Immunotherapy Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Oncolytic Virus Cancer Immunotherapy Market Status by Type

    • 3.1 Oncolytic Virus Cancer Immunotherapy Type Introduction
      • 3.1.1 Monoclonal Antibodies
      • 3.1.2 Checkpoint Inhibitors
      • 3.1.3 Oncoloytic Viral Therapies and Cancer Vaccines
    • 3.2 Global Oncolytic Virus Cancer Immunotherapy Market by Type
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Oncolytic Virus Cancer Immunotherapy Market Status by Application

    • 4.1 Oncolytic Virus Cancer Immunotherapy Segment by Application
      • 4.1.1 Lung Cancer
      • 4.1.2 Breast Cancer
      • 4.1.3 Colorectal Cancer
      • 4.1.4 Melanoma
      • 4.1.5 Prostate Cancer
      • 4.1.6 Head and neck Cancer
      • 4.1.7 Ovarian Cancer
      • 4.1.8 Pancreatic Cancer
      • 4.1.9 Others
    • 4.2 Global Oncolytic Virus Cancer Immunotherapy Market by Application
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Oncolytic Virus Cancer Immunotherapy Market Status by Region

    • 5.1 Global Oncolytic Virus Cancer Immunotherapy Market by Region
    • 5.2 North America Oncolytic Virus Cancer Immunotherapy Market Status
    • 5.3 Europe Oncolytic Virus Cancer Immunotherapy Market Status
    • 5.4 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Status
    • 5.5 Central & South America Oncolytic Virus Cancer Immunotherapy Market Status
    • 5.6 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Status

    6 North America Oncolytic Virus Cancer Immunotherapy Market Status

    • 6.1 North America Oncolytic Virus Cancer Immunotherapy Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Oncolytic Virus Cancer Immunotherapy Market Status

    • 7.1 Europe Oncolytic Virus Cancer Immunotherapy Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Status

    • 8.1 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Oncolytic Virus Cancer Immunotherapy Market Status

    • 9.1 Central & South America Oncolytic Virus Cancer Immunotherapy Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Status

    • 10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Type and by Application

    • 12.1 Global Oncolytic Virus Cancer Immunotherapy Sales Value Forecast (2022-2027)
    • 12.2 Global Oncolytic Virus Cancer Immunotherapy Forecast by Type
    • 12.3 Global Oncolytic Virus Cancer Immunotherapy Forecast by Application

    13 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Region/Country

    • 13.1 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Pfizer
      • 14.1.1 Company Information
      • 14.1.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.1.3 Pfizer Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Novartis AG
      • 14.2.1 Company Information
      • 14.2.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.2.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 MultiVir
      • 14.3.1 Company Information
      • 14.3.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.3.3 MultiVir Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Merck & Co., Inc.
      • 14.4.1 Company Information
      • 14.4.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.4.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Lokon Pharma
      • 14.5.1 Company Information
      • 14.5.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.5.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Genelux Corporation
      • 14.6.1 Company Information
      • 14.6.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.6.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 F Hoffman-La Roche
      • 14.7.1 Company Information
      • 14.7.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.7.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Crusade Laboratories
      • 14.8.1 Company Information
      • 14.8.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.8.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Cell Genesys
      • 14.9.1 Company Information
      • 14.9.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Bristol-Myers Squibb
      • 14.10.1 Company Information
      • 14.10.2 Oncolytic Virus Cancer Immunotherapy Product Introduction
      • 14.10.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Biovex
    • 14.12 AstraZeneca
    • 14.13 Amgen

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Oncolytic Virus Cancer Immunotherapy market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Oncolytic Virus Cancer Immunotherapy industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Oncolytic Virus Cancer Immunotherapy market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Oncolytic Virus Cancer Immunotherapy Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Oncolytic Virus Cancer Immunotherapy market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Oncolytic Virus Cancer Immunotherapy Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Oncolytic Virus Cancer Immunotherapy industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      Monoclonal Antibodies
      Checkpoint Inhibitors
      Oncoloytic Viral Therapies and Cancer Vaccines

      Segmented by Application
      Lung Cancer
      Breast Cancer
      Colorectal Cancer
      Melanoma
      Prostate Cancer
      Head and neck Cancer
      Ovarian Cancer
      Pancreatic Cancer
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Pfizer
      Novartis AG
      MultiVir
      Merck & Co., Inc.
      Lokon Pharma
      Genelux Corporation
      F Hoffman-La Roche
      Crusade Laboratories
      Cell Genesys
      Bristol-Myers Squibb
      Biovex
      AstraZeneca
      Amgen

      Buy now